JP2010514455A5 - - Google Patents

Download PDF

Info

Publication number
JP2010514455A5
JP2010514455A5 JP2009544412A JP2009544412A JP2010514455A5 JP 2010514455 A5 JP2010514455 A5 JP 2010514455A5 JP 2009544412 A JP2009544412 A JP 2009544412A JP 2009544412 A JP2009544412 A JP 2009544412A JP 2010514455 A5 JP2010514455 A5 JP 2010514455A5
Authority
JP
Japan
Prior art keywords
lymphocytes
composition
antigen
composition according
cytotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009544412A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010514455A (ja
JP5452231B2 (ja
Filing date
Publication date
Priority claimed from GBGB0700058.1A external-priority patent/GB0700058D0/en
Application filed filed Critical
Publication of JP2010514455A publication Critical patent/JP2010514455A/ja
Publication of JP2010514455A5 publication Critical patent/JP2010514455A5/ja
Application granted granted Critical
Publication of JP5452231B2 publication Critical patent/JP5452231B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009544412A 2007-01-03 2008-01-03 化学的に修飾した正常な細胞由来の抗腫瘍ワクチン Expired - Fee Related JP5452231B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0700058.1 2007-01-03
GBGB0700058.1A GB0700058D0 (en) 2007-01-03 2007-01-03 Anti-tumor vaccine based on normal cells
PCT/EP2008/050050 WO2008081035A1 (en) 2007-01-03 2008-01-03 Anti-tumor vaccine derived from normal chemically modified cells

Publications (3)

Publication Number Publication Date
JP2010514455A JP2010514455A (ja) 2010-05-06
JP2010514455A5 true JP2010514455A5 (cg-RX-API-DMAC10.html) 2012-10-25
JP5452231B2 JP5452231B2 (ja) 2014-03-26

Family

ID=37759205

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009544412A Expired - Fee Related JP5452231B2 (ja) 2007-01-03 2008-01-03 化学的に修飾した正常な細胞由来の抗腫瘍ワクチン

Country Status (14)

Country Link
US (2) US10023839B2 (cg-RX-API-DMAC10.html)
EP (1) EP2102331B1 (cg-RX-API-DMAC10.html)
JP (1) JP5452231B2 (cg-RX-API-DMAC10.html)
AT (1) ATE522600T1 (cg-RX-API-DMAC10.html)
AU (1) AU2008203730B2 (cg-RX-API-DMAC10.html)
CY (1) CY1112668T1 (cg-RX-API-DMAC10.html)
DK (1) DK2102331T3 (cg-RX-API-DMAC10.html)
ES (1) ES2372713T3 (cg-RX-API-DMAC10.html)
GB (1) GB0700058D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20110899T1 (cg-RX-API-DMAC10.html)
PL (1) PL2102331T3 (cg-RX-API-DMAC10.html)
PT (1) PT2102331E (cg-RX-API-DMAC10.html)
SI (1) SI2102331T1 (cg-RX-API-DMAC10.html)
WO (1) WO2008081035A1 (cg-RX-API-DMAC10.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011421B1 (ru) * 2008-08-26 2009-02-27 Петр Генриевич ЛОХОВ Способ получения противоопухолевой вакцины
US8467973B2 (en) 2009-07-28 2013-06-18 Promising Future, Llc Pairing processes for preparing alloreactive cytotoxic T cells
US8666674B2 (en) 2009-07-28 2014-03-04 Promising Future, Llc Pairing processes for preparing reactive cytotoxic T cells
US9211321B2 (en) 2009-10-27 2015-12-15 Immunicum Ab Method for proliferation of antigen-specific T cells
GB201013443D0 (en) 2010-08-11 2010-09-22 Cytovac As Compositions and methods for producing dendritic cells
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
KR102349677B1 (ko) 2015-05-28 2022-01-12 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
KR20230005428A (ko) 2015-05-28 2023-01-09 카이트 파마 인코포레이티드 T 세포 요법을 위한 진단 방법
IL292504B2 (en) 2015-10-20 2024-01-01 Kite Pharma Inc -methods of preparing t cells for t cell therapy
NZ746700A (en) 2016-04-01 2023-04-28 Kite Pharma Inc Bcma binding molecules and methods of use thereof
SG10201912519VA (en) 2016-04-01 2020-02-27 Kite Pharma Inc Chimeric receptors and methods of use thereof
KR102427334B1 (ko) 2016-04-01 2022-08-03 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
EP3583129B1 (en) 2017-02-14 2021-11-03 Kite Pharma, Inc. Cd70 binding molecules and methods of use thereof
WO2018169922A2 (en) 2017-03-13 2018-09-20 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
CN110475571B (zh) 2017-04-01 2023-04-04 Avm生物技术有限责任公司 细胞免疫疗法前细胞毒性预调理的替代
KR20190130024A (ko) 2017-04-03 2019-11-20 카이트 파마 인코포레이티드 최적화된 다기능 t 세포를 포함하는 키메라 수용체 t 세포를 사용하는 치료
BR102018008260A2 (pt) 2017-04-24 2020-04-28 Kite Pharma, Inc. domínios de ligação ao antígeno humanizado e métodos de uso
US12097218B2 (en) 2017-05-26 2024-09-24 Kite Pharma, Inc. Methods of making and using embryonic mesenchymal progenitor cells
CN111315403A (zh) 2017-09-15 2020-06-19 凯德药业股份有限公司 用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统
EP3684816B1 (en) 2017-09-22 2024-05-29 Kite Pharma, Inc. Chimeric polypeptides and uses thereof
EP3697500A1 (en) 2017-10-18 2020-08-26 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
WO2019099707A1 (en) 2017-11-16 2019-05-23 Kite Pharma, Inc Modified chimeric antigen receptors and methods of use
AU2019206724A1 (en) 2018-01-15 2020-07-16 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1BB agonist
WO2019152957A1 (en) 2018-02-02 2019-08-08 Arizona Board Of Regents On Behalf Of Arizona State University Dna-chimeric antigen receptor t cells for immunotherapy
CA3090793C (en) 2018-02-16 2024-10-08 Kite Pharma, Inc. MODIFIED MULTIPOTENTED STEM CELLS, AND METHODS OF PREPARATION AND USE
CN119656304A (zh) 2018-04-12 2025-03-21 凯德药业股份有限公司 使用肿瘤微环境的特征的嵌合受体t细胞治疗
KR102734592B1 (ko) 2018-06-01 2024-11-27 카이트 파마 인코포레이티드 키메라 항원 수용체 t 세포 요법
US20210155941A1 (en) 2018-06-22 2021-05-27 Kite Pharma Eu B.V. Compositions and methods for making engineered t cells
AU2019314452B2 (en) 2018-08-02 2022-12-08 Kite Pharma, Inc Chimeric antigen receptor therapy T cell expansion kinetics and uses thereof
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
EP3632446B3 (en) 2018-10-03 2024-01-24 AVM Biotechnology, LLC Immunoablative therapies
KR20250116790A (ko) 2018-12-12 2025-08-01 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
WO2020208054A1 (en) 2019-04-12 2020-10-15 Cytovac A/S Method for preparation of cancer/testis antigen-specific t-cells
CN114206346A (zh) 2019-05-03 2022-03-18 凯德药业股份有限公司 施用嵌合抗原受体免疫疗法的方法
CN114391021B (zh) 2019-06-21 2026-01-16 凯德药业股份有限公司 TGF-β受体和使用方法
WO2021046134A1 (en) 2019-09-03 2021-03-11 Allogene Therapeutics, Inc. Methods of preparing t cells for t cell therapy
IL292665B2 (en) 2019-11-06 2026-02-01 Kite Pharma Inc Chimeric antigen receptor T cell therapy
WO2021168375A1 (en) 2020-02-20 2021-08-26 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
US20230293530A1 (en) 2020-06-24 2023-09-21 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
KR20230084470A (ko) 2020-08-14 2023-06-13 카이트 파마 인코포레이티드 면역 세포 기능의 향상
EP4501951A3 (en) 2020-08-25 2025-04-30 Kite Pharma, Inc. T cells with improved functionality
AU2021369507B2 (en) 2020-10-28 2025-06-26 Kite Pharma, Inc. Flow cytometric method for characterization of t-cell impurities
WO2022140159A1 (en) 2020-12-24 2022-06-30 Kite Pharma, Inc. Prostate cancer chimeric antigen receptors
WO2022150582A1 (en) 2021-01-10 2022-07-14 Kite Pharma, Inc. T cell therapy
EP4281545A1 (en) 2021-01-21 2023-11-29 CytoVac A/S Method for t-cell expansion and related medical applications
JP2024507199A (ja) 2021-02-20 2024-02-16 カイト ファーマ インコーポレイテッド 免疫療法を選択するための遺伝子マーカー
KR20230155521A (ko) 2021-03-11 2023-11-10 카이트 파마 인코포레이티드 면역 세포 기능의 향상
US12337035B2 (en) 2021-04-16 2025-06-24 Kite Pharma, Inc. TACI binding molecules
EP4323943A1 (en) 2021-04-16 2024-02-21 Kite Pharma, Inc. Methods and systems for scheduling a patient-specific immunotherapy procedure
KR20230173179A (ko) 2021-05-14 2023-12-26 카이트 파마 인코포레이티드 키메라 항원 수용체 t세포 요법
AU2022282266B2 (en) 2021-05-24 2025-09-18 Kite Pharma, Inc. NKG2D-based chimeric antigen receptor
WO2022261061A1 (en) 2021-06-08 2022-12-15 Kite Pharma, Inc. Gpc3 binding molecules
WO2022269019A1 (en) 2021-06-25 2022-12-29 Cytovac A/S Method for preparation of cytotoxic t lymphocytes with broad tumour-specific reactivity and characteristics of early differentiation cells
WO2023278553A1 (en) 2021-07-01 2023-01-05 Kite Pharma, Inc. Closed-system and method for autologous and allogeneic cell therapy manufacturing
US20230103457A1 (en) 2021-07-02 2023-04-06 Kite Pharma, Inc. Method for identifying variants in gene products from gene constructs used in cell therapy applications
US20230060292A1 (en) 2021-07-26 2023-03-02 Kite Pharma, Inc. Split chimeric antigen receptors and methods of use
KR20240027077A (ko) 2021-07-30 2024-02-29 카이트 파마 인코포레이티드 세포 요법-유도 독성의 모니터링 및 관리
US20230303655A1 (en) 2021-10-18 2023-09-28 Kite Pharma, Inc. Signaling domains for chimeric antigen receptors
CN118742810A (zh) 2022-02-15 2024-10-01 凯德药业股份有限公司 从免疫疗法预测不良事件
WO2023247324A1 (en) 2022-06-24 2023-12-28 Cytovac A/S Novel combination treatment with adoptive cellular therapy
US20240091261A1 (en) 2022-08-26 2024-03-21 Kite Pharma, Inc. Immune cell function
JP2026508791A (ja) 2022-10-28 2026-03-13 カイト ファーマ インコーポレイテッド 免疫療法の有効性及び永続的奏効の改善
TWI882495B (zh) 2022-10-28 2025-05-01 美商凱特製藥公司 用於將免疫療法最佳化之因素
CN120917153A (zh) 2023-03-17 2025-11-07 凯德药业股份有限公司 肿瘤微环境对免疫疗法疗效的影响
US20250161361A1 (en) 2023-11-01 2025-05-22 Kite Pharma, Inc. Factors for optimizing immunotherapy efficacy
US20250262300A1 (en) 2024-02-16 2025-08-21 Kite Pharma, Inc. Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
US20250290154A1 (en) 2024-03-04 2025-09-18 Kite Pharma, Inc. Predictive markers for immunotherapy
TW202604957A (zh) 2024-05-03 2026-02-01 美商凱特製藥公司 嵌合受體及其使用方法
US20250382383A1 (en) 2024-05-31 2025-12-18 Kite Pharma, Inc. Tricistronic constructs for anti-gpc3 car
TW202607133A (zh) 2024-07-08 2026-02-16 美商凱特製藥公司 用於對活細胞施加機械力以產生表型反應的系統及方法
WO2026084968A1 (en) 2024-10-14 2026-04-23 Kite Pharma, Inc. Biomarker based standards and methods of use
US20260224626A1 (en) 2024-11-04 2026-08-06 Kite Pharma, Inc. Biomarkers related to immunotherapy efficacy
WO2026136591A1 (en) 2024-12-18 2026-06-25 Kite Pharma, Inc. Jaml transmembrane and co-signaling domains for chimeric antigen receptors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines

Similar Documents

Publication Publication Date Title
HRP20110899T1 (hr) Protutumorsko cjepivo dobiveno iz normalnih, kemijski modificiranih stanica cd4+
JP6134763B2 (ja) ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
AU2003203051B2 (en) Cancer therapy
JP2015512866A5 (cg-RX-API-DMAC10.html)
JP2013535218A5 (cg-RX-API-DMAC10.html)
Pizzurro et al. Dendritic cell-based vaccine efficacy: aiming for hot spots
Schneiders et al. Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection
Taniguchi et al. Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy
JP2013177430A5 (cg-RX-API-DMAC10.html)
Ning et al. β‐glucan restores tumor‐educated dendritic cell maturation to enhance antitumor immune responses
JP2014514927A5 (cg-RX-API-DMAC10.html)
Kobayashi et al. Fever-range whole-body heat treatment stimulates antigen-specific T-cell responses in humans
Huarte et al. Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma
Shui et al. β-glucan from Aureobasidium pullulans augments the anti-tumor immune responses through activated tumor-associated dendritic cells
Choi et al. The function of memory CD8+ T cells in immunotherapy for human diseases
JP2014533938A5 (cg-RX-API-DMAC10.html)
CN109762788A (zh) 一种car-t细胞的制备方法
Kogo et al. Suppression of murine tumour growth through CD 8+ cytotoxic T lymphocytes via activated DEC‐205+ dendritic cells by sequential administration of α‐galactosylceramide in vivo
Lichtenegger et al. Induction of antigen-specific T-cell responses through dendritic cell vaccination in AML: results of a phase I/II trial and ex vivo enhancement by checkpoint blockade
Liseth et al. Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience
Gritzapis et al. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice
Xu et al. Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine
Al Saihati Overview of Dendritic Cell Vaccines as Effective Approaches in Cancer Immunotherapy.
Peng et al. EWS/FLI-l peptide-pulsed dendritic cells induces the antitumor immunity in a murine Ewing's sarcoma cell model
Iwabuchi et al. Against Lung Cancer and Head and